A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen
Condition: Metastatic Pancreatic Cancer Interventions: Drug: Donafenib; Drug: S1 Sponsor: Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Pancreas | Pancreatic Cancer | Research | Study